• Citer

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane

par Kaufman, Peter P.A.;Perez, Edith A;Olivo, Martin;He, Yi;Dutcus, Corina C.E.;Awada, Ahmad ;Twelves, Chris;Velikova, Galina;Yelle, Louise;Cortes, Javier
Référence Journal of clinical oncology, 33, 6, page (594-601)
Publication Publié, 2015-02

Article révisé par les pairs

• Détails
• Contenu

Titre:	Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
Auteur:	Kaufman, Peter P.A.; Perez, Edith A; Olivo, Martin; He, Yi; Dutcus, Corina C.E.; Awada, Ahmad; Twelves, Chris; Velikova, Galina; Yelle, Louise; Cortes, Javier
Informations sur la publication:	Journal of clinical oncology, 33, 6, page (594-601)
Statut de publication:	Publié, 2015-02
Sujet CREF:	Cancérologie
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:doi/10.1200/JCO.2013.52.4892
	info:scp/84923205214